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Abstract
In 2012, the World Health Organization (WHO) updated its policy on intermittent preventive treat-
ment in pregnancy with sulphadoxine–pyrimethamine (IPTp-SP). A global recommendation to
revise the WHO policy on the treatment of malaria in the first trimester is under review. We con-
ducted a retrospective study of the national policy adoption process for revised IPTp-SP dosing in
four sub-Saharan African countries. Alongside this retrospective study, we conducted a prospect-
ive policy adoption study of treatment of first trimester malaria with artemisinin combination
therapies (ACTs). A document review informed development and interpretation of stakeholder
interviews. An analytical framework was used to analyse data exploring stakeholder perceptions of
the policies from 47 in-depth interviews with a purposively selected range of national level stake-
holders. National policy adoption processes were categorized into four stages: (1) identify policy
need; (2) review the evidence; (3) consult stakeholders and (4) endorse and draft policy. Actors at
each stage were identified with the roles of evidence generation; technical advice; consultative and
statutory endorsement. Adoption of the revised IPTp-SP policy was perceived to be based on
strong evidence, support from WHO, consensus from stakeholders; and followed these stages.
Poor tolerability of quinine was highlighted as a strong reason for a potential change in treatment
policy. However, the evidence on safety of ACTs in the first trimester was considered weak. For
some, trust in WHO was such that the anticipated announcement on the change in policy would
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allay these fears. For others, local evidence would first need to be generated to support a change in
treatment policy. A national policy change from quinine to ACTs for the treatment of first trimester
malaria will be less straightforward than experienced with increasing the IPTp dosing regimen des-
pite following the same policy processes. Strong leadership will be needed for consultation and
consensus building at national level.
Keywords: Policy, malaria
Introduction
Malaria in pregnancy (MiP) causes adverse effects for both the
mother and baby including increased risk of maternal anaemia, low
birthweight and prematurity (Desai et al., 2007). The clinical effects
of MiP depend on the intensity of malaria transmission, the parasite
species and the level of immunity in pregnant women. There are
three main strategies for prevention and control of MiP in sub-
Saharan Africa (SSA), namely Long-Lasting Insecticidal Nets, inter-
mittent preventive treatment with sulphadoxine–pyrimethamine
(IPTp-SP) and effective case management of clinical malaria and an-
aemia (WHO Regional Office for Africa, 2004). IPTp-SP is the de-
livery of a treatment dose of the antimalarial drug SP given at
prespecified times for the prevention of malaria, regardless of the
presence of symptoms or confirmed malaria infection. This study
addresses policies on both IPTp-SP and effective case management
of first trimester malaria.
In terms of IPTp-SP, reports of increasing resistance to SP in
parts of SSA (Chico et al., 2015) (Desai et al., 2017) have led to
questioning of the continued efficacy of IPTp-SP among malaria
control programmes. IPTp-SP was withdrawn in Rwanda in 2008
[Ministere de la Santé (MINISANTE), Institut National de la
Statistique au Rwanda (INSR), 2009] and alternative drugs for IPTp
(Desai et al., 2015) and alternative strategies, primarily intermittent
screening and treatment (Tagbor et al., 2015), have been investi-
gated in other countries. Findings of a meta-analysis of two vs three
or more doses of IPTp with SP (Kayentao et al., 2013) were pre-
sented at WHO’s Evidence Review Group (WHO-ERG) on MiP in
July 2012 who, in turn, presented their recommendations to WHO’s
Malaria Policy Advisory Committee (MPAC) in September 2012
(WHO Malaria Policy Advisory Committee, 2012). This led WHO
to update its original two-dose IPTp policy to ‘a dose of SP at every
ANC visit in the second and third trimester, at least one month
apart’. The policy was subsequently communicated to WHO’s
African Member States (WHO Global Malaria Programme, 2013)
and several countries have now ratified the updated policy and/or
begun implementation (Henry et al., 2018).
For first trimester treatment of MiP, WHO recommends oral
quinine (with or without clindamycin) for the case management of
uncomplicated malaria in the first trimester, and artemisinin
combination therapies (ACTs) or quinine or artesunate (AS) plus
clindamycin in the second and third trimesters (WHO, 2010a). A re-
cent systematic review of case management practices among health-
care providers revealed poor adherence to treatment guidelines by
trimester across a range of countries in SSA (Hill et al., 2014).
Whilst ACTs are the first-line treatment for malaria in both children
and adults across SSA, WHO does not currently recommend use of
the artemisinin class of compounds in the first trimester of preg-
nancy because of insufficient safety data in early pregnancy in
humans (Dellicour et al., 2007; Ward et al., 2007), unless this is the
only treatment immediately available (WHO, 2010a). Yet systemat-
ic prescription of ACTs in the first trimester has been reported in
several African countries (Hill et al., 2014; Riley et al., 2016).
Furthermore, drugs that are no longer recommended in national
treatment policies, such as SP (recommended for IPTp only) and
chloroquine (CQ) (because of known high levels of parasite resist-
ance to CQ) (Bloland, 2001), continue to be used. In addition, the
use of artemisinin monotherapies is a major threat to the develop-
ment of artemisinin resistance in the Africa region, as has occurred
in parts of southeast Asia (WHO, 2010b; Duong et al., 2012).
In 2015, a meta-analysis of observational studies on the risk of
adverse pregnancy outcomes associated with first-trimester treat-
ment with artemisinin derivatives and quinine (Dellicour et al.,
2017) was presented to a WHO-ERG (WHO, 2015). The meta-
analysis concluded that compared to quinine, artemisinin treatment
in the first trimester was not associated with an increased risk of
miscarriage or stillbirth. The results were also reviewed by WHO’s
MPAC in 2015 (WHO Malaria Policy Advisory Committee, 2016b)
which recommended the review of the WHO Guidelines for the
treatment of malaria to consider the timely inclusion of ACTs as a
first-line therapeutic option for uncomplicated falciparum malaria,
which was subsequently endorsed by WHO’s Technical Expert
Group on Malaria Chemotherapy in December 2017 (Global
Malaria Programme, 2015). Countries will then review the new
WHO recommendation and make the decision whether to adopt the
recommendation within national policy.
Broadly within malaria control, policy studies have documented
and analysed barriers to policy making in East Africa (Paul et al.,
2015), the changing of first line treatment for malaria (Williams
KEY MESSAGES
• National policy decision-makers are responsible for the translation of global policies to national policies and their implementation.
There is a lack of understanding of the variability in policy processes and factors influencing this.
• Our retrospective study of a prevention policy and prospective analysis of a treatment policy, found that the main drivers of policy
adoption were: the methodological quality of the research, the relevance of the data to the local context and its prospects for effective
implementation. Trust in WHO policy processes could override these factors.
• These findings contribute to gaps in understanding the translation of global to national policies.
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et al., 2004), the non-normative process of adoption of larval source
management (Tesfazghi et al., 2015) and development of global pol-
icies for intermittent preventive treatment in infants (IPTi) and sea-
sonal malaria chemoprevention (SMC) (D’Souza and Parkhurst,
2018). In control of MiP, studies have explored evidence for, and
delays in policy change (Crawley et al., 2007), documented the
adoption of the revised IPTp-SP policy across countries of SSA
(Henry et al., 2018) but have not interrogated the policy adoption
process and influences on this process.
We conducted a retrospective study of the policy adoption pro-
cess at the national level for the revised global IPTp-SP policy
(revised in October 2012) (World Health Organization, 2012) and a
prospective policy adoption study for a future policy on treatment
of first trimester malaria with ACTs (WHO Malaria Policy
Advisory Committee, 2016a).
Methods
Study sites
The study was undertaken in Kenya, Mali, Malawi and The Gambia
between February 2017 and February 2018. The epidemiology of
malaria varies across the four countries. Kenya has four major mal-
aria epidemiological zones: endemic, highland epidemic, semi-arid
and seasonal and low risk, determined mainly by altitude, rainfall
patterns and temperature; in Mali, malaria is endemic in the central
and southern regions (where >90% of the population lives),
epidemic in the north and highly seasonal; in Malawi, malaria is in-
tense across the country with local variation in intensity and in The
Gambia malaria transmission is heterogenous across the country
(very low to low prevalence in western and central Gambia and
moderate prevalence in eastern Gambia), and highly seasonal.
MiP policies and timelines
The timelines for global and national policy adoption for each policy
are provided in Figure 1, which includes the retrospective and pro-
spective periods of the study in relation to IPTp-SP and ACTs, re-
spectively. The policy on treatment of first trimester malaria with
ACTs (WHO Malaria Policy Advisory Committee, 2016a) was
under review by the WHO Malaria Chemotherapy TEG and was
not adopted in any of the countries at the time of the study. The ra-
tionale for studying both of these policies simultaneously was that it
provided the opportunity to use lessons learned from the retrospect-
ive IPTp-SP policy adoption to support and manage the prospective
first trimester malaria treatment policy adoption (Walt et al., 2008).
Analytical framework
An analytical framework was developed (Figure 2) to explore what
happened and why with adoption of the revised IPTp-SP policy, and
what is likely to happen with adoption of the policy on first trimes-
ter treatment of MiP and why (Walt et al., 2008). Our focus was the
adoption of WHO global policy to national policy. We defined
adoption as the national decision-making process for the policy
Figure 1 Timeline of WHO policies and recommendations for treatment and prevention of MiP in relation to study
Figure 2 Analytical framework adapted from Walt (1994) and Tesfazghi et al. (2015)
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change in the country. The analytical framework provided a guide
to our study tool development and analysis. Our framework was
adapted from the policy triangle framework of Walt and Gilson
(Walt and Gilson, 1994) including policy content, policy context,
policy process, actors and power; and Tesfazghi et al. (2015) who
described the functions of actors in the normative process of policy
adoption for vector control in Nigeria. In our adapted framework,
policy content is the technical content of the policy; process are the
stages of the adoption process; context is not just the wider distal so-
cial, political and economic influences but more proximal factors
within the realist concept of context as ‘the characteristics of the
conditions in which the interventions are introduced’ (Pawson and
Tilley 1997); and actors are individuals or institutions involved in or
with an influence on policy decision-making. Our concept of context
thus included perceptions of stakeholders on policy legitimacy, evi-
dence and power.
Driven by our aim to understand the policy processes and actors
we extrapolated from the functions of actors suggested by Tesfazghi
et al. (2015) to describe four stages of the policy adoption process:
Stage 1: identify a [policy] need; Stage 2: review the evidence; Stage
3: consult stakeholders and Stage 4: endorse and draft policy. We
recognize that these stages may not in practice follow one after the
other in a linear fashion (Sabatier, 2007) and that they may occur
more than once. However, defining these stages aided our explor-
ation of how different institutions and individual actors interacted
within the policy adoption process, what roles they took, and what
factors influenced their decision-making within these roles.
We assumed that perceived legitimacy, credibility and salience
were important in the policy adoption of IPTp-SP in our study coun-
tries and were likely to be important for first trimester treatment of
malaria with ACTs as was shown by D’Souza and Parkhurst recently
in the global development process of two malaria control policies
(D’Souza and Parkhurst, 2018). These policies were IPTi and inter-
mittent preventive treatment of children under 5 years of age, which
is now re-named as SMC. Legitimacy is the perception that evidence
generation and use was unbiased; credibility that the evidence was of
sufficient strength and quality and salience that the evidence was rele-
vant to the needs of the decision-makers (Cash et al., 2003). We were
particularly interested in the capacity that stakeholders had to act and
direct or influence the decision-making process of policy adoption
and examined this through a power lens (Sriram et al., 2018).
Document review
A document review of published and unpublished national docu-
ments was first undertaken. Documents reviewed included: organo-
grams and structures of ministries of health; national malaria
policies, strategies and guidelines; national reproductive health poli-
cies, strategies and guidelines and President’s Malaria Initiative
(PMI) operational plans (Table 1). Documents were primarily
accessed at the national level through national level contacts among
the authors and requests to stakeholders and were supplemented by
online searches for peer-reviewed publications on malaria and MiP
policies in PubMed. Information was extracted from the documents
into an excel spreadsheet on the policy making context, the content
of malaria and reproductive health policy documents, and the key
stakeholders involved. This information was used in the selection of
stakeholders, development of the theme guides and analysis of the
interview data.
Selection of stakeholders
Stakeholders were purposively selected to include individuals and
institutions with an interest in either the revised IPTp-SP policy and/
or the first trimester treatment of MiP policy, who were affected by
these policies or who, because of their position had or could have an
active or passive influence on the decision-making and implementa-
tion processes (Varvasovszky and Brugha, 2000). The document re-
view formed the starting point for the identification of key
individuals and institutions and was supplemented following discus-
sion with the study lead in each country. The final list for each coun-
try was formulated at a stakeholder selection session, where lists
were compared and adjustments made. The final list broadly
included stakeholders from: Ministry of Health (MoH) or other na-
tional institutions; National Malaria Control Programmes
(NMCPs), National Reproductive Health Programmes (NRHPs);
United Nations (UN) or bilateral institutions; Non-governmental
Organisations (NGOs); international donors and academia. An it-
erative process was applied whereby additional stakeholders identi-
fied as relevant during the interviews were approached and invited
to take part in the study.
Data collection
In-depth interviews were conducted in: Nairobi, Kenya; Bamako,
Mali; Blantyre and Lilongwe, Malawi and Banjul, The Gambia.
Stakeholders were given information about the study and their writ-
ten consent to be interviewed obtained. Interviews were then con-
ducted by a trained social scientist in each country partner research
institution using a theme guide. The theme guide related specifically
to revised IPTp-SP policy (World Health Organization, 2012) and
the first trimester treatment of MiP recommendation (WHO
Malaria Policy Advisory Committee, 2016b), and was standard
across the four countries and included: formal policy making struc-
tures; perceptions of policy legitimacy; prospective or retrospective
support or opposition from competing interest groups; perceived fit
within the health system of the intervention; anticipated future bene-
fits and costs. However, an iterative process was applied to the inter-
views, such that additional themes were included and further
interrogated as they arose during the interviews. These new themes
were then included in subsequent interviews.
Interviews were conducted in English except for Bamako where
they were conducted in French. Data collected during stakeholder
interviews was digitally recorded and supplemented by handwritten
field notes. Data were transcribed, and translated (Bamako), and
imported into NVivo (QSR International) Version 11 for data man-
agement and analysis.
Data analysis
A coding framework was constructed where the primary coding
nodes were based on the elements of our analytical framework. This
deductive coding was supplemented by inductive coding based on
additional themes that emerged from the data using content analysis
(Bernard, 2006). Coding was conducted by one author but analysed
and interpreted by three authors to enhance objectivity.
For each stage of policy adoption the process and actors with a
specific role were identified. Study participants were assigned an an-
onymous code during data analysis which related to their category
of stakeholder (see below), and these were used to label quotes to
ensure anonymity. This approach was followed for both the retro-
spective and prospective studies.
The Standards of Reporting Qualitative Research (SRQR) which
provides clear standards for reporting through a list of 21 essential
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items was used to guide the reporting of findings (O’Brien et al.,
2014). The SRQR does not specifically include an analytical frame-
work within its reporting guidance on qualitative approach, but
does include guiding theory more broadly.
Results
A total of 47 interviews were completed with stakeholders
across the four countries (Table 2). The results are presented
according to each of the analytical framework themes: policy con-
tent for both the revised IPTp-SP (World Health Organization,
2012) and the prospective treatment of first trimester malaria
with ACT policies (WHO Malaria Policy Advisory Committee,
2016a): the policy processes, roles and actors for each of the
four stages of the policy adoption process using examples from
the adoption of revised IPTp-SP policy; and policy context.
Context included the presentation of stakeholder perceptions of
policy legitimacy, stakeholder power, followed by presentation of
perceptions of the revised IPTp-SP policy (World Health
Organization, 2012) and the treatment of first trimester malaria.
Findings from the document review are presented and cited where
relevant.
Table 1 Documents reviewed by category
Country Category and document
Structure of MoH and organograms
Kenya Republic of Kenya National Malaria Control Programme: malaria fact sheet http://www.nmcp.or.ke/index.php/about-us
Malawi Ministry of Health. 2011. Malawi Health Sector Strategic Plan 2011–2016. Lilongwe.
Mali 1. Programme Nationale de Lutte Contre le Paludisme. Politique Nationale de Lutte Contre le Paludisme au Mali. Bamako (Undated
document).
2. Programme Nationale de Lutte Contre le Paludisme. 2013. Plan National de Suivi/Evaluation 2013–2017.
The Gambia The Gambia: Ministry of Health and Social Welfare. 2012. National Health Policy ‘Health is Wealth’ 2012–2020. Banjul.
National malaria policies, strategies and guidelines
Kenya 1. National Malaria Control Programme. 2014. Kenya Malaria Strategy 2009–2018 (Revised 2014). Nairobi.
2. Ministry of Public Health and Sanitation and Ministry of Medical Services. 2010. National Guidelines for the Diagnosis, Treatment
and Prevention of Malaria in Kenya. Nairobi.
3. Republic of Kenya National Malaria Control Programme: http://www.nmcp.or.ke/index.php/resource-centre/download-centre/
case-managment
4. Ministry of Health Division of Malaria Control. 2005. Malaria communication strategy. 5. National Malaria Control Programme
(NMCP), Kenya National Bureau of Statistics (KNBS) and ICF International. 2016. Kenya Malaria Indicator Survey 2015. Nairobi,
Kenya and Rockville, Maryland, USA: NMCP, KNBS and ICF International.
Malawi 1. National Malaria Control Programme. Malaria Strategic Plan 2011–2015 Towards Universal Access. Lilongwe.
2. National Malaria Control Programme. 2011. Revised Guide for the Management of Malaria. Lilongwe.
3. National Statistical Office (NSO) [Malawi] and ICF International. 2016. Malawi Demographic and Health Survey 2015–16: Key
Indicators Report. Zomba, Malawi and Rockville, Maryland, USA: NSO and ICF International.
Mali 1. Programme Nationale de Lutte Contre le Paludisme. 2017. Plan Strategique de Lutte Contre le Paludisme 2013–2017.
2. Programme Nationale de Lutte Contre le Paludisme. Politique Nationale de Lutte Contre le Paludisme au Mali. Bamako (there are
no dates for this document).
3. Programme Nationale de Lutte Contre le Paludisme. 2013. Plan National de Suivi/Evaluation 2013–2017.
4. Cellule de Planification et de Statistique du Secteur Sante Developpement Social et Promotion de la Famille. Canevas de synthese
des rapports d’evaluation 2015 et de programmation 2017 du programme national de lute contre le paludisme.
The Gambia 1. National Malaria Control Programme. National Malaria Strategic Plan 2014–2020.
2. Ministry of Health and Social Welfare. 2009. Malaria Control in The Gambia Strategic Plan 2008–2015. Banjul.
3. The Gambia Bureau of Statistics (GBOS) and ICF International. 2014. The Gambia Demographic and Health Survey 2013. Banjul,
The Gambia and Rockville, Maryland, USA: GBOS and ICF International.
4. National Malaria Control Programme. 2015. The Gambia National Monitoring and Evaluation Plan for Malaria 2014–2020.
National reproductive health policies, strategies and guidelines
Kenya 1. Ministry of Health. 2007. National Reproductive Health Policy: Enhancing Reproductive Health Status for all Kenyans. Nairobi.
2. Division of Reproductive Health and National AIDS and STI Control Programme, Kenya. National Curriculum on Sexuality and
Sexual Health Training for Health Service Providers: Facilitator’s Manual. June 2011.
Malawi 1. Ministry of Health. 2006. National Reproductive Health Strategy 2006–2010.
2. Ministry of Health. 2012. Road Map for Accelerating the reduction of Maternal and Neonatal Mortality and Morbidity in Malawi.
Lilongwe.
3. Ministry of Health. 2009. National Sexual and Reproductive Health and Rights (SRHR) Policy. Lilongwe.
Mali Ministere de la Santé & Programme National de Lutte Contre le Paludisme. 2012. Directives nationales pour la gestion et la distribu-
tion gratuite des moustiquaires impregnées d’insecticide de longue duree aux femmes enceintes et aux enfants de moins de cinq ans
et de la sulfadoxine pyrimethamine á la femme enceinte.
The Gambia 1. Department of State for Health. National Reproductive Health Policy 2007–2014.
2. Sundby J. 2014. A rollercoaster of policy shifts: global trends and reproductive health policy in The Gambia. Global Public Health
9: 894–909.
3. Ministry of Women’s Affairs. The Gambia National Gender Policy 2010–2020. Banjul.
PMI operational plans
Kenya Kenya: President’s Malaria Initiative (PMI). Kenya Malaria Operational Plan FY 2016.
Malawi Malawi: President’s Malaria Initiative (PMI). Malawi Malaria Operational Plan FY 2016.
Mali Mali: President’s Malaria Initiative (PMI). Mali Malaria Operational Plan FY 2016.
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Policy content
IPTp-SP policy
IPTp-SP has been national policy for prevention of MiP in Kenya,
Malawi, Mali and The Gambia for more than two decades ( ,
2017, 2018a,b,c) with policies stating at least two or at least three
doses to be given to pregnant women at least 1 month apart start-
ing in the second trimester (Programme Nationale de Lutte Contre
le Paludisme; Ministry of Public Health and Sanitation and
Ministry of Medical Services, 2010; National Malaria Control
Programme, 2011; van Eijk et al., 2011). The study countries have
updated this policy within the last 5 years to reflect the WHO
revised policy on IPTp-SP (National Malaria Control Programme,
2014, 2015; National Malaria Control Programme. Ministry of
Health and Social Welfare, 2014) Each country has stated that
IPTp-SP should be given to pregnant women at least 1 month apart
on each visit or each scheduled visit to antenatal clinic (ANC).
Treatment of first trimester malaria policy
In all study countries, quinine is currently recommended for the
treatment of malaria in pregnant women during the first trimester,
and ACT in the second and third trimesters (Ministry of Public
Health and Sanitation and Ministry of Medical Services, 2010;
National Malaria Control Programme, 2011; National Malaria
Control Programme; Programme Nationale de Lutte Contre le
Paludisme, 2013). Combining quinine with clindamycin supports
the move away from monotherapies. Based on the reports of stake-
holders, there was an almost universal lack of adherence to this cur-
rent policy on treatment for first trimester MiP (Hill et al., 2014;
Riley et al., 2016). Clindamycin was reported not to have been pro-
cured in Kenya, Malawi and The Gambia. ACTs are not entirely
contraindicated for first trimester treatment; for example, the
Kenyan policy on treatment of first trimester MiP states that arte-
mether–lumefantrine (AL) must not be withheld if quinine is not
available (Ministry of Health, 2016) and in Malawi, ACTs are rec-
ommended for first trimester women with confirmed treatment fail-
ure to quinine plus clindamycin (Ministry of Health, 2015). The
prospective policy currently under discussion at WHO is the replace-
ment of quinine with ACTs for the treatment of first trimester
malaria.
Policy process, roles and actors
Interviews with stakeholders initially focused on general health pol-
icy processes, followed by the process through which the number of
doses of IPTp-SP in the revised policy was changed. Comments were
then sought on potential issues relating to the anticipated
announcement of a global policy shift on the treatment of malaria in
first trimester pregnant women from quinine to ACTs. Policy
changes for malaria control were reportedly led by the NMCP in all
four countries. In addition, stakeholders across all countries
reported that policy changes involving MiP required close collabor-
ation with NRHPs.
Stage one: identify a policy need
Policy needs were identified through global initiatives based on
WHO recommendations, international standards and successful
pilots at global level, through advocates, activists or government
departments. Whilst the IPTp-SP dosing change was a recommenda-
tion of WHO, awareness of stakeholders within countries and there-
fore the route to initial identification of a need varied. In Kenya it
was based on the 2012 revised WHO recommendations on IPTp-SP
(World Health Organization, 2012) and subsequently the NMCP
decided that changing IPTp-SP dosing was a priority. In The
Gambia, the dosing changes were a recommendation of the 2012
WHO Malaria Programme Review and were followed by forums
where focal points from the NMCP discussed the rationale of the
change. In Malawi, it was considered a simple process to adapt the
guidance from WHO and no further evidence generation or synthe-
ses were undertaken. In Mali, key stakeholders taking part in inter-
national meetings were aware of other countries moving to 3 doses
following which, consultation between the NMCP and the Malaria
Research and Training Centre (MRTC) led to the policy process
being initiated.
Ultimately a need should be identified through evidence, whether
internationally or locally driven. Evidence generation was reported
to be done mainly by researchers, both international and local,
including the Kenya Medical Research Institute (KEMRI) (Kenya),
College of Medicine (Malawi) and MRTC (Mali) (Figure 3).
Researchers from MRTC led the review of evidence that led to the
change in international recommendations on IPTp-SP dosing
(Kayentao et al., 2013).
Stage two: review the evidence
Each of the four countries reported the presence of national tech-
nical working groups (TWGs) with the role of reviewing malaria
evidence for policy. In Kenya, Malawi and Mali TWGs were estab-
lished groups with regular meetings, whilst in The Gambia, they
were ad hoc task forces established as needed. Where the evidence
was external to the country options were to: do a pilot or operation-
al research study in-country to generate locally derived evidence; or
review the evidence and consider whether it reflects the country situ-
ation, is implementable and likely to give the expected results. Often
both options were reported as having been conducted concurrently.
The nature of the evidence and who had produced or was recom-
mending the evidence was felt to be important. It was felt that if
WHO were recommending a malaria policy, then the studies were
sufficient and further studies would build on this evidence. For ex-
ample, in Malawi the evidence on the policy of using rapid diagnos-
tic tests (RDTs) to diagnose malaria was accepted based on WHO
evidence and then national studies were undertaken to test different
types and brands of RDTs. In Kenya, the availability of local evi-
dence on use of ACT for treatment of severe malaria meant that the
policy was adopted quickly. However, lack of local evidence led to
the MRTC decision in Mali to stall the adoption of ACT use in se-
cond trimester until it could be gathered, as they felt the internation-
al evidence did not reflect the Malian context.
Table 2 Interviewees by institution and country
Institution Kenya Malawi Mali The Gambia Total
MoH, other national
institution
3 3 4 3 13
NMCP 3 4 6 1 14
Reproductive health
programme
(NRHP)/other na-
tional programme
2 1 1 0 4
UN, bilateral 3 0 2 2 7
NGO 3 1 2 1 7
International donor 0 0 0 1 1
Academia 0 1 0 0 1
14 10 15 8 47
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All countries reported that the evidence for changing IPTp-SP
dosing had been reviewed by their TWGs and that supporting this
policy was straight forward, that is their decision-making was not
complicated because the evidence was available and had been
reviewed and endorsed by WHO.
A MiP TWG was mentioned by stakeholders in Kenya, Malawi
and Mali, together with a Sexual and Reproductive Health (SRH)
TWG in Malawi. The TWGs generally involved a wide range of
experts and stakeholders. In Malawi and Kenya, the MiP TWG is
chaired by a member of National Reproductive Health Programme,
with the secretariat in the NMCP. In Mali, the MiP TWG is chaired
by NMCP, with the Reproductive Health Programme amongst the
members.
Stage three: consult stakeholders
The critical importance of stakeholder consultation in defining and
drafting policies was stated by participants in all four countries. In
Kenya, it was the role of the NMCP to bring together partners to
consider the feasibility when deciding whether to adopt malaria pol-
icies, and in Mali, for MiP, the NMCP had a similar role but under
the umbrella of the TWG. Consultative partners reported that only
two meetings were needed in The Gambia to bring about the change
in IPTp-SP dosing.
Consultation on the revised IPTp-SP policy being developed
involved stakeholders from the MoH and development partners as
well as those involved in implementing this intervention.
Representatives from the Counties or Districts for example, districts
health officers, were often included. In The Gambia, the revised
IPTp-SP policy development in malaria control was reported to have
included stakeholder consultation on the strengths, weaknesses,
opportunities and threats of the new policy.
Stage four: draft policy, statutory policy making and strategy
endorsement
In most countries, standards and policy procedures are reviewed
every 5 years. If the required update is close to official revision time
then countries will wait and include it, otherwise they make an ad-
dendum or technical note while waiting for official date of policy re-
view. In the case of these MiP policies the relevant national
documents are the National Malaria Strategic Plan and the National
Malaria Treatment Guidelines. Sometimes, as reported by The
Gambia, consultants are hired to facilitate the consultation meetings
and help draft the policy.
The analysis of revising the IPTp-SP policy across the four coun-
tries revealed it was often an advisory committee that made a final
decision on the IPTp-SP policy, that is, endorsed the policy. The def-
inition of this committee varied across the four countries. In Kenya,
TWGs present recommendations to the Malaria Inter-Agency
Coordinating Committee (MICC) for endorsement. Endorsement
includes consideration of whether the recommendation reflects the
country situation, is implementable and likely to produce expected
results. The Principal Secretary, MoH in Kenya is chair of the
MICC. A similar body in Malawi is the National Malaria Advisory
committee which meets only twice a year. Once a policy has been
endorsed, it is signed by a senior member of the Ministry of Health.
Policy context
Policy legitimacy
Stakeholder perceptions of the legitimacy of a new or revised policy
will contribute to a positive context for adoption of the policy.
When asked what made a policy legitimate, participants across the
four countries reported the following key criteria, which aligned
with the four stages of the policy adoption process: (1) the policy
was endorsed by the appropriate authority, which usually meant the
relevant ministry within government, (2) the policy was based on
WHO recommendations, (3) the formulation of the policy had
involved key stakeholders and (4) the policy was based on evidence.
Additional factors described by stakeholders in some countries
included that the policy should address a need ‘on the ground’, im-
prove health, be feasible to implement and be acceptable to the
public.
Figure 3 Stages of the policy adoption process, actors and their role
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Stakeholder power
Stakeholders in all four countries strongly identified with the bur-
eaucratic power of the leadership role of the WHO in guiding rec-
ommendations on MiP control policies (Sriram et al., 2018). UN
and bilateral donors were particularly strong in their expression of
the leadership role of the WHO:
Respondent (R): WHO is the truth. So WHO says it has to hap-
pen, it has to happen . . . (Kenya_UN/bilateral).
R: If WHO already approves it is no longer worth doing oper-
ational studies (Mali_UN/bilateral).
Some stakeholders were aware of the WHO ERG and MPAC
processes in the development of WHO policy guidelines. The role of
the national research institutions and TWGs in reviewing the evi-
dence from WHO was valued in all countries, however, in The
Gambia external support was sometimes called upon.
The policy adoption process for any MiP control strategies was
routinely led by NMCP in all four countries with the support of
NRHP. Each country, with the exception of The Gambia, had a
MiP TWG which was chaired by either NMCP or NRHP.
The guidance of national research institutions in reviewing inter-
national malaria control policies for potential adoption was said to
be particularly strong in Mali, indicating a power based on technical
expertise (Sriram et al., 2018). It was suggested by a stakeholder
that MRTC could question WHO guidance if local evidence was not
judged to be sufficient. For example, the change in policy on the use
of ACTs in the second and third trimesters was delayed in Mali as
MRTC were not comfortable that the study data was representative
of the Malian population, as most of the studies used to support the
change were conducted in Asia. The relationship between the
NMCP and MRTC in Mali was very strong, with the MRTC being
described as the ‘technical arm’ of NMCP.
Despite the defined structures and processes for malaria policy
making, stakeholders remarked on the political pressures experi-
enced within the process, such as political pressure on the WHO
from donors at the international level, and from pharmaceutical
companies at the national level. In Malawi, a knowledge translation
unit was developed within the MoH to strengthen the use of evi-
dence for decision-making, but some participants felt that platform
was understaffed and often side-lined during the policy making
process.
Evidence
Revised intermittent preventive treatment policy
The IPTp-SP dosing policy change was perceived to have been
backed by strong evidence and endorsed by the WHO. As such, the
decision of whether to revise this policy was reported to have been
an easy one.
R: It was quite easy because evidence was there that giving three,
four doses is more beneficial than limiting the dose to two, so as
a result it was an easy process (The Gambia_MoH/other govern-
ment body).
The major challenge in increasing the doses of IPTp-SP reported
by stakeholders related to perceptions of the feasibility of imple-
menting the policy. Many stakeholders, across all four countries,
expressed doubt that high coverage of the new dosing schedule
could be achieved as coverage targets for the previous schedule,
which included fewer doses, were not yet met.
First trimester treatment
We now present the perceptions of stakeholders on the current and
potential future policies on first trimester treatment for MiP.
Current policy.. Compliance to quinine for the treatment of first tri-
mester MiP was reported as poor across the four countries both in
terms of health worker prescribing practices and women’s adherence
to the treatment. Health workers sometimes prescribed ACTs, des-
pite contravening current policy guidance, due to poor quinine toler-
ance among women and a dislike of the bitter taste.
R: The only challenge that we get with this policy is that
. . .. . ..from the health workers, yes they have the information but
at times they would still be able to prescribe AL Just because of
the mother is being able to tolerate. Yeah, so there is less compli-
ance when it comes to quinine vis a vis AL and you will get that
the health workers at times just go ahead and give the AL
(Kenya_NRHP).
Perceptions on resistance to quinine varied with some stakehold-
ers believing that resistance was already a problem and others feel-
ing sure that there was no resistance to quinine, with no clear
differences across the countries.
In Mali, some stakeholders said they would welcome a shift
from quinine to ACTs for treatment in the first trimester as some
health providers were unsure whether to use quinine or ACTs in the
first trimester due to their inability to accurately determine gesta-
tional age. The switch to ACTs would simplify the treatment guide-
lines, particularly in areas where community health workers
(CHWs) are delivering services. CHWs are not currently authorized
to prescribe ACTs due to the contraindication in first trimester. A se-
cond concern expressed by the TWG was that by treating pregnant
women in the community, ANC attendance would fall.
R: I think there are concerns; the first difficulty is the age of preg-
nancy, whether it is the first trimester of pregnancy, whether or
not we should give ACTs. The gestational age is a serious prob-
lem with our providers especially in CSCOM [Community
Health Centres] where it is the matrons who are in charge of
that, it is true, there are clinical signs but it can’t be said with
confidence . . . (Mali_UN/Bilateral).
Potential future policy.. Participants listed their perceptions of many
benefits of ACTs including ACTs are very effective antimalarials;
are more readily available; combination therapies are better than
monotherapies; have fewer side effects than quinine; have shorter
dosing schedule and fewer compliance issues.
R: Midwifes said that pregnant women are always complaining
about quinine because of its adverse effects . . .. and nurses don’t
want to do the prescription because of side effect. Often the num-
ber of doses is reduced to avoid side effects. The treatment is al-
ways not correctly done. Women take just few tablets for few
days. Even if the parasitaemia is reduced, the time of treatment is
not enough and this can lead to severe malaria (Mali_NMCP).
Concerns were expressed that there may be resistance to ACTs
as there have been reports of treatment failures.
Most stakeholders did not have a preference for a specific ACT,
amongst those who did – AL was mentioned based on efficacy stud-
ies (Malawi) and dihydroartemisinin–piperaquine (DP), or that se-
lection depended on the safety profile of the specific antimalarial
and the evidence. Several stakeholders reported that they would
worry about using amodiaquine (Malawi and Mali) due to its im-
pact on the liver.
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R: I would have to look at the scientific evidence that is available,
but I know that what we are usually worried about is the partner
drug. The ACTs come with fast acting drug and long acting
drugs. Fast acting will be artesunate or artemisinin derivative and
usually there is very little or not at all safety concerns because it
is not available for a long time . . . but we have artemether-
lumefantrine, piperaquine and some use SP and amodiaquine,
those are long acting drugs . . . amodiaquine that is the one I
would be a little bit hesitant . . . but you have to look at the evi-
dence (NRHP/other national programme).
Evidence required to support a change from current to future policy
for first trimester treatment of malaria.. Perceptions on the evidence
required to introduce ACTs for treatment in the first trimester in the
future focused on safety and efficacy. The main safety concern was
teratogenic effects as well as other adverse reactions, with no recog-
nition that data on adverse effects was from animal models only.
The need to carefully balance the potential risks of the drug with the
benefits in terms of improved outcomes of MiP was acknowledged.
Stakeholders from Malawi and The Gambia felt that the evidence
from ‘WHO studies’ was not yet conclusive and they were awaiting
an official announcement from WHO. There were concerns from
stakeholders in Malawi that WHO guidance would be based on sys-
tematic reviews that included studies from outside the region and ra-
ther should be based on empirical studies from neighbouring
countries, and from Kenya that local evidence of safety and efficacy
was required, not just global evidence. Several stakeholders men-
tioned that there must have been a reason for non-use of ACTs in
the first trimester, having been deemed unsafe initially, and that
pharmacovigilance should be in place for this policy change.
R: With artesunate there is a problem since in the first trimester
and in safety studies artesunate has shown that it is teratogenic
and embryotoxic. But there is no evidence in terms of research.
Because there is no evidence the assumption is that we can pro-
ceed to artesunate since it has better efficacy than quinine. But I
think. . .change to artesunate in the second and third trimester
when that risk of teratogenic and embryotoxicity is gone
(Malawi_MoH/national institution).
Participants drew parallels on their experience of changing pol-
icy for first line treatment of malaria from SP to ACTs based on na-
tional drug resistance studies and guidance from WHO on
‘threshold’ levels of SP resistance at which a change should be initi-
ated. It was acknowledged that lessons on tolerability could be
learned from other countries already using the drug.
Stakeholder position on first trimester treatment with
ACTs
Most participants felt there would not be any opposition to a future
policy change to ACT for first trimester treatment and could not
name an organization that would oppose it. Most participants
reported that if the evidence was good and the recommendation
came from WHO and was endorsed by the NMCP then the policy
would be supported by the wider development community and other
stakeholder groups.
However, responses on potential opposition to a future policy
change to ACT for first trimester treatment related mainly to evi-
dence being viewed as unsatisfactory. In Kenya it was felt that stud-
ies from civil society showing evidence counter to the
recommendation could potentially be a risk, although no such stud-
ies had been reported thus far. Other potential triggers of opposition
included critics in the scientific community (Mali), medical
practitioners if they are not convinced of safety of the drugs (Kenya,
Malawi), and potential challenges from the private sector (The
Gambia).
Discussion
In this study, covering a timeline from 2012 to 2018, we investi-
gated the perceptions of national level stakeholders on the adoption
of two global malaria control policies into national level policies in
four SSA countries; the 2012 revised IPTp-SP policy (World Health
Organization, 2012) (using a retrospective lens) and a potential fu-
ture policy change on the use of ACTs for first trimester treatment
of MiP (WHO Malaria Policy Advisory Committee, 2016a).
The policy adoption process for changing the IPTp-SP dosing
regimen was very similar across the study countries, each using the
four stage policy adoption process extrapolated from functions of
actors in Tesfazghi et al. (2015) including: identification of policy
need, review of evidence, stakeholder consultation and drafting pol-
icy/policy endorsement. The prompt for initiating the policy change
process in all countries was the recommendation from WHO (WHO
Global Malaria Programme, 2013). Stakeholders reported that the
WHO endorsement was a requirement for the legitimacy of a mal-
aria control policy, however not all policies recommended by WHO
are adopted by countries as was the case with IPTi (D’Souza and
Parkhurst, 2018).
There is a large and growing literature on the use of research evi-
dence in policy making including models of the way in which the
evidence is used and the process within which it is used (Gilson
et al., 2018). Policy formulation at the global level for the revised
IPTp-SP policy (World Health Organization, 2012) was a top-down
model primarily focused on research evidence from a systematic re-
view (Kayentao et al., 2013). The policy adoption process at the na-
tional level in each of the four countries however, followed an
interactive research utilization model where the research evidence
was part of a wider process involving a range of stakeholders, with
participation of stakeholders perceived as a requirement for the pol-
icy to be legitimate (Buse et al., 2012).
The revised IPTp-SP WHO recommendation (World Health
Organization, 2012) was perceived to be based on good quality,
credible evidence. The evidence was perceived as relevant as the
included studies were all from SSA and covered West, East and
Southern Africa regions: Burkina Faso, Kenya, Malawi, Mali,
Tanzania and Zambia, hence there was no requirement for addition-
al local evidence. This evidence also underwent a high level of peer
review by a WHO ERG before being passed to the MPAC for fur-
ther review and endorsement. None of the stakeholders interviewed
across the four countries perceived there to have been any national
opposition to this policy, nor any deviation from the normative pol-
icy change process. The evidence generation and review process
were seen as legitimate.
The policy process for malaria control interventions is not al-
ways this straightforward, particularly but not only where the evi-
dence base is not strong and widely accepted. Long delays were
experienced in changing from chloroquine to SP as first line malaria
treatment policy in SSA despite strong evidence (Williams et al.,
2004) at a time when drug policy change processes were less formu-
lated and institutionalized. In other cases, the normative process had
not been followed due to strong stakeholder interests and percep-
tions, and stakeholder power. For example, the policy decision on
scaling up larviciding in Nigeria deviated from the normative pro-
cess, involving powerful actors and a commercial incentive, and
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excluding those usually involved in evidence generation, advisory
and consultative roles (Tesfazghi et al., 2015). Consensus for other
malaria control policies has struggled despite the evidence being
considered credible. A recent policy study found that the evidence
for SMC was generated from randomized control trials (RCTs) in
the seasonal transmission settings in which it would be applied and
results were similar. Conversely, the RCTs for IPTi were done in a
variety of transmission settings as IPTi is an intervention that can be
implemented throughout the year. These different transmission and
drug resistance settings led to less consistent results in the trials and
therefore a less consistent efficacy message (D’Souza and Parkhurst,
2018). This study highlights the differing perceptions of the legitim-
acy of the process of SMC compared with that of IPTi, partly not
only due to the type of evidence but also due to the policy structures,
e.g. MPAC was in place for SMC but not IPTi, and lessons learned
from IPTi, but also the perceived advocacy for IPTi from technical
actors.
Interviews with stakeholders across the four countries suggest
that the future adoption of treatment in first trimester with ACTs
would be less straight forward than for changing the IPTp-SP regi-
men. A future first trimester treatment policy change would involve
more actors such as drug regulators given this is a new indication
for ACTs and an off-label use, as the producers do not currently rec-
ommend their use in the first trimester. The evidence for use of
ACTs in the first trimester was perceived to be less strong and there-
fore less convincing, particularly on safety, which was considered
paramount by all actors. Respondents noted that whilst the meta-
analysis which led to the change in IPTp-SP policy was based on
findings from RCTs in a number of countries, the evidence for the
adoption of ACTs for first trimester MiP was from a meta-analysis
of observational studies. However, RCTs to assess the efficacy of
ACTs vs quinine in the first trimester of pregnancy have not been
conducted as they have been considered unethical, and the sample
size required to provide any guidance on the risk of congenital
abnormalities prohibitive (Dellicour et al., 2017). Concerns were
expressed on the representativeness of the population in which the
first trimester safety studies were conducted. Despite the meta-
analysis containing six studies from SSA, the title of the publication
indicated that the analyses were based on data from Africa and Asia
and this may have been taken at face value. Although adverse events
from ACTs may be similar in Africa and Asia, the differences in the
nature of clinical malaria in the two continents, due to differing
transmission levels, are widely known. Participants felt pharmacovi-
gilance studies at the country level, and the support to conduct
them, would be required (Talisuna et al., 2006; Dellicour et al.,
2007, 2008; Tinto et al., 2015). Prospective pharmacovigilance
studies are the only way to increase the evidence base for safety in
the first trimester to capture first trimester exposures, especially in
the first few weeks of pregnancy, when women often do not know
that they are pregnant or do not admit to their pregnancy.
Whilst many stakeholders expressed reservations about the cred-
ibility and salience of some MiP evidence, others had sufficient trust
in the WHO and the legitimacy of the global processes and would
have confidence in a future national policy change to ACTs for
treatment in the first trimester if/when recommended by WHO. For
some participants, the need for local evidence was paramount.
Stakeholder consultation and the reaching of consensus in each
country would require strong leadership. In Mali, given the dynamic
between the NMCP and MRTC, MRTC support for the policy
change was important.
Our examination and description of the policy adoption stages,
functions and identity of stakeholders within this process will be
useful when interrogating and navigating the policy process for
other malaria control interventions. Application of our simple ana-
lytical framework highlighted the strong influence, in national adop-
tion of global policy, of the perceived applicability or salience of
evidence to the country not just credibility or quality of evidence,
which resonates with the findings of D’Souza and Parkhurst in their
study on IPTi and SMC (D’Souza and Parkhurst, 2018). Malaria
and/or MiP TWGs had a strong role in decision-making on national
adoption of global policies. The two communities theory of research
utilization proposes that the research and policy communities oper-
ate within different cultures (Caplan, 1979). However, for countries
in this study, the malaria and MiP TWGs bring researchers and
decision-makers together to make joint recommendations. Whilst
we were able to gain an understanding of the wider policy making
structures within our study countries, there would be value in fur-
ther exploration of the decision-making processes, relationships and
power within such national TWGs.
Policy analysis is often limited by lack of access to clear docu-
mentation in terms of content and across programmes and depart-
ments (Walt et al., 2008; Gomez et al., 2014). In this study, there
was a lack of clarity on policy dates. The study was also limited by
the availability of potential interviewees. Despite the study team’s
best efforts to interview all selected interviewees some key stake-
holders were not available. This challenge accounted to a large ex-
tent for the difference in numbers of stakeholders interviewed
between the countries. There was confusion in some interviews with
stakeholders on the national policy process for updating national
policy guidelines, for example the national malaria strategy update,
often a 5-year cycle vs new drug regimens or changes to a specific
intervention.
Conclusions
National policy adoption of three or more doses of IPTp-SP was
seen to be based on strong evidence, a recommendation from WHO,
consensus from stakeholders, and followed the normative process
for updating an existing policy. A future change from quinine to
ACTs for first trimester treatment of MiP is likely to be supported
due to the poor tolerability of quinine compared to ACTs and be-
cause it would simplify provider practice. However, concerns about
safety in the first trimester and lack of evidence at the country level
will need to be addressed to garner full support for national policy
adoption. Strong national leadership will be needed to reach stake-
holder consensus and policy adoption.
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